Can We Afford the New Era of Lung Cancer Survival?ByChinmay Jani, MD,Gilberto Lopes, MDFebruary 19th 2026Durvalumab boosts survival in limited-stage SCLC, yet US costs miss value thresholds, fueling urgent debates on access and pricing.